Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Clinical trial NCT05579366 · RECRUITING

Trial details

NCT number: NCT05579366
Sponsor: Genmab
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

High Grade Epithelial Ovarian Cancer High Grade Serous Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer Endometrial Cancer Non-small Cell Lung Cancer Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)Mesothelioma Breast Adenocarcinoma Triple Negative Breast Cancer Hormone Receptor-positive/Her2 Negative Breast Cancer Platinum-resistant Ovarian Cancer (PROC)

Start date: 2022-12-07
Primary completion: 2027-07-01
Enrollment: 884

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.